Ahmet, B. Et Al. 2012. A COMPARISON OF XELIRI PLUS BEVACIZUMAB WITH FOLFIRI PLUS BEVACIZUMAB AS FIRST-LINE SETTING IN PATIENTS WITH METASTATIC COLORECTAL CANCER. 14th World Congress on Gastrointestinal Cancer of the European-Society-for-Medical-Oncology (ESMO) , (Barcelona, Spain), 98-99.

Ahmet, B., UYGUN, K., Kaya, S., Ustaalioglu, B. B. O., Yildiz, R., Temiz, S., ... Seker, M.(2012). A COMPARISON OF XELIRI PLUS BEVACIZUMAB WITH FOLFIRI PLUS BEVACIZUMAB AS FIRST-LINE SETTING IN PATIENTS WITH METASTATIC COLORECTAL CANCER . 14th World Congress on Gastrointestinal Cancer of the European-Society-for-Medical-Oncology (ESMO) (pp.98-99). Barcelona, Spain

Ahmet, Bilici Et Al. "A COMPARISON OF XELIRI PLUS BEVACIZUMAB WITH FOLFIRI PLUS BEVACIZUMAB AS FIRST-LINE SETTING IN PATIENTS WITH METASTATIC COLORECTAL CANCER," 14th World Congress on Gastrointestinal Cancer of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 2012

Ahmet, Bilici Et Al. "A COMPARISON OF XELIRI PLUS BEVACIZUMAB WITH FOLFIRI PLUS BEVACIZUMAB AS FIRST-LINE SETTING IN PATIENTS WITH METASTATIC COLORECTAL CANCER." 14th World Congress on Gastrointestinal Cancer of the European-Society-for-Medical-Oncology (ESMO) , Barcelona, Spain, pp.98-99, 2012

Ahmet, B. Et Al. (2012) . "A COMPARISON OF XELIRI PLUS BEVACIZUMAB WITH FOLFIRI PLUS BEVACIZUMAB AS FIRST-LINE SETTING IN PATIENTS WITH METASTATIC COLORECTAL CANCER." 14th World Congress on Gastrointestinal Cancer of the European-Society-for-Medical-Oncology (ESMO) , Barcelona, Spain, pp.98-99.

@conferencepaper{conferencepaper, author={Bilici Ahmet Et Al. }, title={A COMPARISON OF XELIRI PLUS BEVACIZUMAB WITH FOLFIRI PLUS BEVACIZUMAB AS FIRST-LINE SETTING IN PATIENTS WITH METASTATIC COLORECTAL CANCER}, congress name={14th World Congress on Gastrointestinal Cancer of the European-Society-for-Medical-Oncology (ESMO)}, city={Barcelona}, country={Spain}, year={2012}, pages={98-99} }